2 Information about abrocitinib, tralokinumab, upadacitinib
Marketing authorisation indication
2.1 Abrocitinib (Cibinqo, Pfizer) is 'indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy'.
2.2 Tralokinumab (Adtralza, Leo) is 'indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy'.
2.3 Upadacitinib (Rinvoq, AbbVie) is 'indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy'.
Dosage in the marketing authorisation
2.4 The dosage schedule for abrocitinib is available in the summary of product characteristics for abrocitinib.
2.5 The dosage schedule for tralokinumab is available in the summary of product characteristics for tralokinumab.
2.6 The dosage schedule for upadacitinib is available in the summary of product characteristics for upadacitinib.
Price
2.7 The list price of abrocitinib is £893.76 for a 28‑pack of 100 mg or 200 mg tablets (excluding VAT, BNF online, accessed March 2022). The company has a commercial arrangement. This makes abrocitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.
2.8 The list price of tralokinumab is £1,070 for a 4‑pack of 150 mg per 1 ml pre-filled syringes (excluding VAT, BNF online, accessed March 2022). The company has a commercial arrangement. This makes tralokinumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.
2.9 The list price of upadacitinib is £805.56 for a 28‑pack of 15 mg modified-release tablets or £1,611.12 for a 28‑pack of 30 mg modified-release tablets (excluding VAT, BNF online, accessed March 2022). The company has a commercial arrangement. This makes upadacitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.